Literature DB >> 28057847

RON Signaling Is a Key Mediator of Tumor Progression in Many Human Cancers.

Najme Faham1, Alana L Welm1.   

Abstract

With an increasing body of literature covering RON receptor tyrosine kinase function in different types of human cancers, it is becoming clear that RON has prominent roles in both cancer cells and in the tumor-associated microenvironment. RON not only activates several oncogenic signaling pathways in cancer cells, leading to more aggressive behavior, but also promotes an immunosuppressive, alternatively activated phenotype in macrophages and limits the antitumor immune response. These two unique functions of this oncogene, the strong correlation between RON expression and poor outcomes in cancer, and the high tolerability of a new RON inhibitor make it an exciting therapeutic target, the blocking of which offers an advantage toward improving the survival of cancer patients. Here, we discuss recent findings on the role of RON signaling in cancer progression and its potential in cancer therapy.
© 2016 Faham and Welm; Published by Cold Spring Harbor Laboratory Press.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28057847     DOI: 10.1101/sqb.2016.81.031377

Source DB:  PubMed          Journal:  Cold Spring Harb Symp Quant Biol        ISSN: 0091-7451


  12 in total

1.  The RTK Interactome: Overview and Perspective on RTK Heterointeractions.

Authors:  Michael D Paul; Kalina Hristova
Journal:  Chem Rev       Date:  2018-12-27       Impact factor: 60.622

2.  Identification of a RON tyrosine kinase receptor binding peptide using phage display technique and computational modeling of its binding mode.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Mol Model       Date:  2017-08-19       Impact factor: 1.810

Review 3.  Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody-drug conjugates as lead drug candidates for clinical trials.

Authors:  Hang-Ping Yao; Sreedhar Reddy Suthe; Xiang-Min Tong; Ming-Hai Wang
Journal:  Ther Adv Med Oncol       Date:  2020-05-12       Impact factor: 8.168

4.  Blocking Short-Form Ron Eliminates Breast Cancer Metastases through Accumulation of Stem-Like CD4+ T Cells That Subvert Immunosuppression.

Authors:  Shu-Chin Alicia Lai; Harika Gundlapalli; H Atakan Ekiz; Amanda Jiang; Elvelyn Fernandez; Alana L Welm
Journal:  Cancer Discov       Date:  2021-12-01       Impact factor: 38.272

5.  A potential signaling axis between RON kinase receptor and hypoxia-inducible factor-1 alpha in pancreatic cancer.

Authors:  Akihisa Kato; Serina Ng; Amalraj Thangasamy; Haiyong Han; Wendi Zhou; Stephane Raeppel; Michael Fallon; Sushovan Guha; Sudhakar Ammanamanchi
Journal:  Mol Carcinog       Date:  2021-08-04       Impact factor: 5.139

Review 6.  Role of Recepteur D'origine Nantais on Gastric Cancer Development and Progression.

Authors:  Sung Yeul Yang; Thi Thinh Nguyen; Trong Thuan Ung; Young Do Jung
Journal:  Chonnam Med J       Date:  2017-09-25

7.  Inhibition of RON kinase potentiates anti-CTLA-4 immunotherapy to shrink breast tumors and prevent metastatic outgrowth.

Authors:  Huseyin Atakan Ekiz; Shu-Chin Alicia Lai; Harika Gundlapalli; Fadi Haroun; Matthew A Williams; Alana L Welm
Journal:  Oncoimmunology       Date:  2018-07-11       Impact factor: 8.110

8.  mTORC1 is a key mediator of RON-dependent breast cancer metastasis with therapeutic potential.

Authors:  Najme Faham; Ling Zhao; Alana L Welm
Journal:  NPJ Breast Cancer       Date:  2018-11-09

9.  Short-form RON (sf-RON) enhances glucose metabolism to promote cell proliferation via activating β-catenin/SIX1 signaling pathway in gastric cancer.

Authors:  Ziliang Wang; Yufei Yang; Shuang Hu; Jian He; Zheng Wu; Zihao Qi; Mingzhu Huang; Rujiao Liu; Ying Lin; Cong Tan; Midie Xu; Zhe Zhang
Journal:  Cell Biol Toxicol       Date:  2020-05-12       Impact factor: 6.691

Review 10.  Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors.

Authors:  Ryuhjin Ahn; Josie Ursini-Siegel
Journal:  Int J Mol Sci       Date:  2021-03-05       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.